NeuroPace (NPCE) plans to end its distribution agreement with DIXI Medical for stereo EEG products to focus on its portfolio for differentiated responsive neurostimulation systems.
The distribution agreement will wind down in Q4 and into the following quarter, NeuroPace said Wednesday in a statement.
NeuroPace maintained its 2025 revenue guidance along with long-range expectations of at least a 20% compound annual growth rate and cash flow breakeven by the end of 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."